Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis

Pugliese D, Felice C, Landi R, Papa A, Guidi L, Armuzzi A

Drug, Healthcare and Patient Safety 2016, 8:1-7

Published Date: 3 February 2016